Cargando…
Hsa-miR-133a-3p, miR-1-3p, GOLPH3 and JUP combination results in a good biomarker to distinguish between prostate cancer and non-prostate cancer patients
The incidence and mortality of Prostate Cancer (PCa) worldwide correlate with age and bad dietary habits. Previously, we investigated the mRNA/miRNA role on PCa development and progression using high fat diet (HFD) fed mice. Here our main goal was to investigate the effect of HFD on the expression o...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9641240/ https://www.ncbi.nlm.nih.gov/pubmed/36387263 http://dx.doi.org/10.3389/fonc.2022.997457 |
_version_ | 1784826054211272704 |
---|---|
author | Duca, Rocío Belén Massillo, Cintia Farré, Paula Lucía Graña, Karen Daniela Moro, Juana Gardner, Kevin Lacunza, Ezequiel De Siervi, Adriana |
author_facet | Duca, Rocío Belén Massillo, Cintia Farré, Paula Lucía Graña, Karen Daniela Moro, Juana Gardner, Kevin Lacunza, Ezequiel De Siervi, Adriana |
author_sort | Duca, Rocío Belén |
collection | PubMed |
description | The incidence and mortality of Prostate Cancer (PCa) worldwide correlate with age and bad dietary habits. Previously, we investigated the mRNA/miRNA role on PCa development and progression using high fat diet (HFD) fed mice. Here our main goal was to investigate the effect of HFD on the expression of PCa-related miRNAs and their relevance in PCa patients. We identified 6 up- and 18 down-regulated miRNAs in TRAMP-C1 mice prostate tumors under HFD conditions using miRNA microarrays. Three down-regulated miRNAs: mmu-miR-133a-3p, -1a-3p and -29c-3p were validated in TRAMP-C1 mice prostate tumor by stem-loop RT-qPCR. Hsa-miR-133a-3p/1-3p expression levels were significantly decreased in PCa compared to normal tissues while hsa-miR-133a-3p was found to be further decreased in metastatic prostate cancer tumors compared to non-metastatic PCa. We examined the promoter region of hsa-miR-133a-3p/1-3p genes and compared methylation at these loci with mature miRNA expression. We found that hsa-miR-1-2/miR-133a-1 cluster promoter hypermethylation decreased hsa-miR-133a-3p/1-3p expression in PCa. GOLPH3 and JUP, two hsa-miR-133a-3p and miR-1-3p predicted target genes, were up-regulated in PCa. ROC analysis showed that the combination of hsa-miR-133a-3p, miR-1-3p, GOLPH3 and JUP is a promising panel biomarker to distinguish between PCa and normal adjacent tissue (NAT). These results link PCa aggressiveness to the attenuation of hsa-miR-133a-3p and miR-1-3p expression by promoter hypermethylation. Hsa-miR-133a-3p and miR-1-3p down-regulation may enhance PCa aggressiveness in part by targeting GOLPH3 and JUP. |
format | Online Article Text |
id | pubmed-9641240 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96412402022-11-15 Hsa-miR-133a-3p, miR-1-3p, GOLPH3 and JUP combination results in a good biomarker to distinguish between prostate cancer and non-prostate cancer patients Duca, Rocío Belén Massillo, Cintia Farré, Paula Lucía Graña, Karen Daniela Moro, Juana Gardner, Kevin Lacunza, Ezequiel De Siervi, Adriana Front Oncol Oncology The incidence and mortality of Prostate Cancer (PCa) worldwide correlate with age and bad dietary habits. Previously, we investigated the mRNA/miRNA role on PCa development and progression using high fat diet (HFD) fed mice. Here our main goal was to investigate the effect of HFD on the expression of PCa-related miRNAs and their relevance in PCa patients. We identified 6 up- and 18 down-regulated miRNAs in TRAMP-C1 mice prostate tumors under HFD conditions using miRNA microarrays. Three down-regulated miRNAs: mmu-miR-133a-3p, -1a-3p and -29c-3p were validated in TRAMP-C1 mice prostate tumor by stem-loop RT-qPCR. Hsa-miR-133a-3p/1-3p expression levels were significantly decreased in PCa compared to normal tissues while hsa-miR-133a-3p was found to be further decreased in metastatic prostate cancer tumors compared to non-metastatic PCa. We examined the promoter region of hsa-miR-133a-3p/1-3p genes and compared methylation at these loci with mature miRNA expression. We found that hsa-miR-1-2/miR-133a-1 cluster promoter hypermethylation decreased hsa-miR-133a-3p/1-3p expression in PCa. GOLPH3 and JUP, two hsa-miR-133a-3p and miR-1-3p predicted target genes, were up-regulated in PCa. ROC analysis showed that the combination of hsa-miR-133a-3p, miR-1-3p, GOLPH3 and JUP is a promising panel biomarker to distinguish between PCa and normal adjacent tissue (NAT). These results link PCa aggressiveness to the attenuation of hsa-miR-133a-3p and miR-1-3p expression by promoter hypermethylation. Hsa-miR-133a-3p and miR-1-3p down-regulation may enhance PCa aggressiveness in part by targeting GOLPH3 and JUP. Frontiers Media S.A. 2022-10-26 /pmc/articles/PMC9641240/ /pubmed/36387263 http://dx.doi.org/10.3389/fonc.2022.997457 Text en Copyright © 2022 Duca, Massillo, Farré, Graña, Moro, Gardner, Lacunza and De Siervi https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Duca, Rocío Belén Massillo, Cintia Farré, Paula Lucía Graña, Karen Daniela Moro, Juana Gardner, Kevin Lacunza, Ezequiel De Siervi, Adriana Hsa-miR-133a-3p, miR-1-3p, GOLPH3 and JUP combination results in a good biomarker to distinguish between prostate cancer and non-prostate cancer patients |
title | Hsa-miR-133a-3p, miR-1-3p, GOLPH3 and JUP combination results in a good biomarker to distinguish between prostate cancer and non-prostate cancer patients |
title_full | Hsa-miR-133a-3p, miR-1-3p, GOLPH3 and JUP combination results in a good biomarker to distinguish between prostate cancer and non-prostate cancer patients |
title_fullStr | Hsa-miR-133a-3p, miR-1-3p, GOLPH3 and JUP combination results in a good biomarker to distinguish between prostate cancer and non-prostate cancer patients |
title_full_unstemmed | Hsa-miR-133a-3p, miR-1-3p, GOLPH3 and JUP combination results in a good biomarker to distinguish between prostate cancer and non-prostate cancer patients |
title_short | Hsa-miR-133a-3p, miR-1-3p, GOLPH3 and JUP combination results in a good biomarker to distinguish between prostate cancer and non-prostate cancer patients |
title_sort | hsa-mir-133a-3p, mir-1-3p, golph3 and jup combination results in a good biomarker to distinguish between prostate cancer and non-prostate cancer patients |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9641240/ https://www.ncbi.nlm.nih.gov/pubmed/36387263 http://dx.doi.org/10.3389/fonc.2022.997457 |
work_keys_str_mv | AT ducarociobelen hsamir133a3pmir13pgolph3andjupcombinationresultsinagoodbiomarkertodistinguishbetweenprostatecancerandnonprostatecancerpatients AT massillocintia hsamir133a3pmir13pgolph3andjupcombinationresultsinagoodbiomarkertodistinguishbetweenprostatecancerandnonprostatecancerpatients AT farrepaulalucia hsamir133a3pmir13pgolph3andjupcombinationresultsinagoodbiomarkertodistinguishbetweenprostatecancerandnonprostatecancerpatients AT granakarendaniela hsamir133a3pmir13pgolph3andjupcombinationresultsinagoodbiomarkertodistinguishbetweenprostatecancerandnonprostatecancerpatients AT morojuana hsamir133a3pmir13pgolph3andjupcombinationresultsinagoodbiomarkertodistinguishbetweenprostatecancerandnonprostatecancerpatients AT gardnerkevin hsamir133a3pmir13pgolph3andjupcombinationresultsinagoodbiomarkertodistinguishbetweenprostatecancerandnonprostatecancerpatients AT lacunzaezequiel hsamir133a3pmir13pgolph3andjupcombinationresultsinagoodbiomarkertodistinguishbetweenprostatecancerandnonprostatecancerpatients AT desierviadriana hsamir133a3pmir13pgolph3andjupcombinationresultsinagoodbiomarkertodistinguishbetweenprostatecancerandnonprostatecancerpatients |